<p>Design Therapeutics（納斯達克代碼：DSGN - 獲取免費報告）於週三發佈了其財報。該公司報告本季度每股收益為（$0.30），超出分析師一致預期的（$0.34）$0.04，Zacks 報道。</p>
<p>獲取 <strong>Design Therapeutics</strong> 的提醒：</p>
<h2>Design Therapeutics 股票表現</h2>
<p>週三中午交易時，Design Therapeutics 股票上漲 $0.31，達到 $6.55。該股票交易了 86,016 股，較其平均交易量 194,359 股有所減少。Design Therapeutics 的 12 個月低點為 $2.60，12 個月高點為 $7.77。該公司的 50 日簡單移動平均為 $6.26，200 日簡單移動平均為 $4.84。該公司的市值為 $3.7302 億，市盈率為 -5.85，貝塔值為 1.67。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Design Therapeutics 股票的 &#34;賣出（d-）&#34;評級。根據 MarketBeat.com 的數據，一位股票研究分析師對該股票給予了賣出評級，目前 Design Therapeutics 的平均評級為 &#34;賣出&#34;。</p>
<p><strong>查看我們關於 Design Therapeutics 的最新報告</strong></p>
<h2>機構資金流入和流出</h2>
<p>幾家對沖基金和其他機構投資者最近買入和賣出了 DSGN 股票。Invesco Ltd. 在第二季度將其在 Design Therapeutics 的持股增加了 26.8%。Invesco Ltd. 目前擁有 14,364 股該公司的股票，價值 $48,000，此前在上個季度購買了額外的 3,033 股。Jane Street Group LLC 在第一季度購買了 Design Therapeutics 的新頭寸，價值約 $70,000。美國銀行公司 DE 在第二季度將其在 Design Therapeutics 的持股增加了 11.1%。美國銀行公司 DE 目前擁有 24,625 股該公司的股票，價值 $83,000，此前在上個季度購買了額外的 2,459 股。Strs Ohio 在第一季度購買了 Design Therapeutics 的新股份，價值約 $87,000。最後，Bridgeway Capital Management LLC 在第二季度將其在 Design Therapeutics 的持股增加了 65.4%。Bridgeway Capital Management LLC 目前擁有 188,200 股該公司的股票，價值 $634,000，此前在上個季度購買了額外的 74,400 股。對沖基金和其他機構投資者持有該公司 56.64% 的股票。</p>
<h2>Design Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Design Therapeutics, Inc 是一家生物製藥公司，專注於研究、設計、開發和商業化小分子治療藥物，以治療美國的遺傳疾病。該公司利用其 GeneTAC 平台設計和開發因核苷酸重複擴展引起的遺傳疾病的治療候選藥物。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Design Therapeutics</li>
<li>投資商品：它們是什麼？如何投資？</li>
<li>目前三隻現金充裕的高增長潛力股票</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>為什麼 Vertical Aerospace 股票在這次飛行測試後可能會翻倍</li>
<li>如何從價值投資中獲利</li>
<li>亞馬遜：突破確認——接下來可能會去哪裏</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Design Therapeutics 嗎？</h2>
<p>在你考慮 Design Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前... 而 Design Therapeutics 並不在名單上。</p>
<p>雖然 Design Therapeutics 目前在分析師中獲得了減持評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DSGN

<p>Design Therapeutics（納斯達克代碼：DSGN）報告的季度每股收益為（$0.30），超出預期$0.04。股價上漲至$6.55，市值為 3.7302 億美元。分析師維持 “賣出” 評級，Weiss Ratings 給予 “賣出（d-）” 評級。機構投資者持有 56.64% 的股份，Invesco 和美國銀行的持股顯著增加。Design Therapeutics 專注於利用其 GeneTAC 平台開發針對遺傳疾病的小分子藥物</p>

<p>Design Therapeutics (NASDAQ:DSGN - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.04, Zacks reports.</p>
<div class="lb-trans"><p>Design Therapeutics（納斯達克代碼：DSGN - 獲取免費報告）於週三發佈了其財報。該公司報告本季度每股收益為（$0.30），超出分析師一致預期的（$0.34）$0.04，Zacks 報道。</p>
</div><p>Get <strong>Design Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Design Therapeutics</strong> 的提醒：</p>
</div><h2>Design Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Design Therapeutics 股票表現</h2>
</div><p>Shares of Design Therapeutics stock traded up $0.31 during mid-day trading on Wednesday, hitting $6.55. 86,016 shares of the stock were exchanged, compared to its average volume of 194,359. Design Therapeutics has a 12 month low of $2.60 and a 12 month high of $7.77. The company has a 50-day simple moving average of $6.26 and a 200 day simple moving average of $4.84. The company has a market capitalization of $373.02 million, a P/E ratio of -5.85 and a beta of 1.67.</p>
<div class="lb-trans"><p>週三中午交易時，Design Therapeutics 股票上漲 $0.31，達到 $6.55。該股票交易了 86,016 股，較其平均交易量 194,359 股有所減少。Design Therapeutics 的 12 個月低點為 $2.60，12 個月高點為 $7.77。該公司的 50 日簡單移動平均為 $6.26，200 日簡單移動平均為 $4.84。該公司的市值為 $3.7302 億，市盈率為 -5.85，貝塔值為 1.67。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Design Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Design Therapeutics currently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Design Therapeutics 股票的 &#34;賣出（d-）&#34;評級。根據 MarketBeat.com 的數據，一位股票研究分析師對該股票給予了賣出評級，目前 Design Therapeutics 的平均評級為 &#34;賣出&#34;。</p>
</div><p><strong>View Our Latest Report on Design Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Design Therapeutics 的最新報告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of DSGN. Invesco Ltd. increased its position in shares of Design Therapeutics by 26.8% during the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company's stock valued at $48,000 after purchasing an additional 3,033 shares during the last quarter. Jane Street Group LLC purchased a new position in Design Therapeutics in the first quarter valued at about $70,000. Bank of America Corp DE increased its stake in shares of Design Therapeutics by 11.1% during the 2nd quarter. Bank of America Corp DE now owns 24,625 shares of the company's stock worth $83,000 after purchasing an additional 2,459 shares during the last quarter. Strs Ohio bought a new stake in shares of Design Therapeutics in the 1st quarter worth approximately $87,000. Finally, Bridgeway Capital Management LLC lifted its stake in Design Therapeutics by 65.4% in the second quarter. Bridgeway Capital Management LLC now owns 188,200 shares of the company's stock valued at $634,000 after purchasing an additional 74,400 shares during the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買入和賣出了 DSGN 股票。Invesco Ltd. 在第二季度將其在 Design Therapeutics 的持股增加了 26.8%。Invesco Ltd. 目前擁有 14,364 股該公司的股票，價值 $48,000，此前在上個季度購買了額外的 3,033 股。Jane Street Group LLC 在第一季度購買了 Design Therapeutics 的新頭寸，價值約 $70,000。美國銀行公司 DE 在第二季度將其在 Design Therapeutics 的持股增加了 11.1%。美國銀行公司 DE 目前擁有 24,625 股該公司的股票，價值 $83,000，此前在上個季度購買了額外的 2,459 股。Strs Ohio 在第一季度購買了 Design Therapeutics 的新股份，價值約 $87,000。最後，Bridgeway Capital Management LLC 在第二季度將其在 Design Therapeutics 的持股增加了 65.4%。Bridgeway Capital Management LLC 目前擁有 188,200 股該公司的股票，價值 $634,000，此前在上個季度購買了額外的 74,400 股。對沖基金和其他機構投資者持有該公司 56.64% 的股票。</p>
</div><h2>Design Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Design Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.</p>
<div class="lb-trans"><p>Design Therapeutics, Inc 是一家生物製藥公司，專注於研究、設計、開發和商業化小分子治療藥物，以治療美國的遺傳疾病。該公司利用其 GeneTAC 平台設計和開發因核苷酸重複擴展引起的遺傳疾病的治療候選藥物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Design Therapeutics</li>
<li>Investing in Commodities: What Are They? How to Invest in Them</li>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Why Vertical Aerospace Stock Could Double After This Flight Test</li>
<li>How to Profit From Value Investing</li>
<li>Amazon: Breakout Confirmed—Here’s Where It Could Go Next</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Design Therapeutics</li>
<li>投資商品：它們是什麼？如何投資？</li>
<li>目前三隻現金充裕的高增長潛力股票</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>為什麼 Vertical Aerospace 股票在這次飛行測試後可能會翻倍</li>
<li>如何從價值投資中獲利</li>
<li>亞馬遜：突破確認——接下來可能會去哪裏</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFNHTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DSGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Design Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Design Therapeutics 嗎？</h2>
</div><p>Before you consider Design Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Design Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前... 而 Design Therapeutics 並不在名單上。</p>
</div><p>While Design Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Design Therapeutics 目前在分析師中獲得了減持評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Design Therapeutics（納斯達克代碼：DSGN）公佈季度財報，每股收益比預期高出 0.04 美元